These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32059498)

  • 21. MTLD, a Database of Multiple Target Ligands, the Updated Version.
    Chen C; Wu M; Cen S; Wu J; Zhou J
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28878188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying the tendency of therapeutic target proteins to bind promiscuous or selective compounds.
    Hu Y; Bajorath J
    PLoS One; 2015; 10(5):e0126838. PubMed ID: 26000736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in multitarget-directed ligands via in silico drug discovery.
    Maddeboina K; Yada B; Kumari S; McHale C; Pal D; Durden DL
    Drug Discov Today; 2024 Mar; 29(3):103904. PubMed ID: 38280625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining the Degree of Promiscuity of Extensively Assayed Compounds.
    Jasial S; Hu Y; Bajorath J
    PLoS One; 2016; 11(4):e0153873. PubMed ID: 27082988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Assessment of Fragment Identification for Multitarget Drug Design.
    Brunst S; Kramer JS; Kilu W; Heering J; Pollinger J; Hiesinger K; George S; Steinhilber D; Merk D; Proschak E
    ChemMedChem; 2021 Apr; 16(7):1088-1092. PubMed ID: 33283450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polypharmacology: challenges and opportunities in drug discovery.
    Anighoro A; Bajorath J; Rastelli G
    J Med Chem; 2014 Oct; 57(19):7874-87. PubMed ID: 24946140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.
    Hu Y; Bajorath J
    AAPS J; 2013 Jul; 15(3):808-15. PubMed ID: 23605807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology.
    Gilberg E; Jasial S; Stumpfe D; Dimova D; Bajorath J
    J Med Chem; 2016 Nov; 59(22):10285-10290. PubMed ID: 27809519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Investigation of Dual-Target-Directed Ligands.
    Lembo V; Bottegoni G
    J Med Chem; 2024 Jun; 67(12):10374-10385. PubMed ID: 38843874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of ultra-fast 2D and 3D ligand and target descriptors for side effect prediction and network analysis in polypharmacology.
    Cortés-Cabrera A; Morris GM; Finn PW; Morreale A; Gago F
    Br J Pharmacol; 2013 Oct; 170(3):557-67. PubMed ID: 23826885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity cliffs produced by single-atom modification of active compounds: Systematic identification and rationalization based on X-ray structures.
    Hu H; Bajorath J
    Eur J Med Chem; 2020 Dec; 207():112846. PubMed ID: 32977219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug promiscuity].
    Guo ZR
    Yao Xue Xue Bao; 2011 Apr; 46(4):361-9. PubMed ID: 21751487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Definition of "Multitargeticity": Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis.
    Sánchez-Tejeda JF; Sánchez-Ruiz JF; Salazar JR; Loza-Mejía MA
    Front Chem; 2020; 8():176. PubMed ID: 32232029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots.
    Gilberg E; Gütschow M; Bajorath J
    ACS Omega; 2019 Jan; 4(1):1729-1737. PubMed ID: 31459430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management.
    Turnaturi R; Arico G; Ronsisvalle G; Pasquinucci L; Parenti C
    Curr Med Chem; 2016; 23(40):4506-4528. PubMed ID: 27781944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creation of a free, Internet-accessible database: the Multiple Target Ligand Database.
    Chen C; He Y; Wu J; Zhou J
    J Cheminform; 2015; 7():14. PubMed ID: 25897329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (Multiple QSAR) Method.
    Wei Y; Li W; Du T; Hong Z; Lin J
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational Multitarget Drug Design.
    Zhang W; Pei J; Lai L
    J Chem Inf Model; 2017 Mar; 57(3):403-412. PubMed ID: 28166637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.
    Reyes-Parada M; Iturriaga-Vasquez P
    Expert Opin Drug Discov; 2016 Oct; 11(10):969-81. PubMed ID: 27552487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationalizing Promiscuity Cliffs.
    Dimova D; Bajorath J
    ChemMedChem; 2018 Mar; 13(6):490-494. PubMed ID: 29024534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.